SCHEMBL23964201

SCHEMBL23964201

Cc1ncnc(N2CCN(Cc3cc4ccccc4[nH]3)CC2)c1C

nearest known ligand 0.58

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
HRH4 Q9H3N8 1/20 0.58
DRD2 P14416 10/20 0.47
DRD3 P35462 10/20 0.47
DRD4 P21917 3/20 0.47
HTR1A P08908 1/20 0.47
ADRA2A P08913 1/20 0.47
ADRA2B P18089 1/20 0.47
ADRA2C P18825 1/20 0.47
OPRK1 P41145 1/20 0.47
HTT P42858 4/20 0.44
SMN1; SMN2 Q16637 4/20 0.44
NPSR1 Q6W5P4 4/20 0.44
KDM4E B2RXH2 3/20 0.44
ALDH1A1 P00352 3/20 0.44
MAPT P10636 3/20 0.44
GAA P10253 2/20 0.44
HPGD P15428 2/20 0.44
HIF1A Q16665 2/20 0.44
LMNA P02545 2/20 0.44
MAPK1 P28482 2/20 0.44

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL30041258 1.00 HRH4 (0.58) HRH4DRD2DRD3DRD4HTR1A
SCHEMBL23932505 0.86 HRH4 (0.53) HRH4DRD2DRD3DRD4HTR1A
SCHEMBL23932545 0.86 DRD2 (0.49) HRH4DRD2DRD3DRD4HTR1A
SCHEMBL30041947 0.86 DRD2 (0.49) HRH4DRD2DRD3DRD4HTR1A
SCHEMBL23932540 0.84 DRD2 (0.40) HRH4DRD2DRD3DRD4HTR1A
SCHEMBL23964232 0.83 HRH4 (0.57) HRH4DRD2DRD3DRD4HTR1A
SCHEMBL23932572 0.83 DRD2 (0.41) HRH4DRD2DRD3DRD4HTR1A
SCHEMBL23964254 0.81 HRH4 (0.60) HRH4DRD2DRD3DRD4HTR1A
SCHEMBL30041015 0.81 HRH4 (0.60) HRH4DRD2DRD3DRD4HTR1A
SCHEMBL23964267 0.80 USP2 (0.64) DRD2DRD4HTR1AADRA2COPRK1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230150980-A1 COLLAGEN 1 TRANSLATION INHIBITORS AND METHODS OF USE THEREOF ANIMA BIOTECH INC. (US) 2023-05-18 US disclosed
US-20230150980-A1 COLLAGEN 1 TRANSLATION INHIBITORS AND METHODS OF USE THEREOF ANIMA BIOTECH INC. (US) 2023-05-18 US disclosed
CN-115427404-A Collagen 1 translation inhibitors and methods of use thereof 艾尼莫生物科技公司 2022-12-02 CN disclosed
WO-2021216665-A9 COLLAGEN 1 TRANSLATION INHIBITORS AND METHODS OF USE THEREOF ANIMA BIOTECH INC. (US) 2021-12-02 WO disclosed
WO-2021216665-A1 COLLAGEN 1 TRANSLATION INHIBITORS AND METHODS OF USE THEREOF ANIMA BIOTECH INC. (US) 2021-10-28 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230150980-A1 COLLAGEN 1 TRANSLATION INHIBITORS AND METHODS OF USE THEREOF COL1A1, COL2A1, COL14A1 HRH4 4471/4885DRD2 4780/4885DRD3 4747/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.